Kyowa Hakko attended the International Society of Sports Nutrition (ISSN) conference, highlighting IMMUSE and EYEMUSE products, according to a press release.
IMMUSE is a Lactococcus lactis strain plasma (LC plasma) discovered by Kyowa Hakko’s parent company, Kirin Holding Company. It works by activating plasmacytoid dendritic cells (pDC), which in turn activate NK, Killer T, Helper T and B cells and support the immune system. IMMUSE is supported by two safety studies and nine effectiveness studies.
Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, said in the press release, “Prolonged high-intensity exercise is known to decrease immune function and increase the risk of upper respiratory tract infections (URTI). It is a serious problem for athletes as URTIs are not only uncomfortable but also decrease training efficiency. There is new evidence that oral ingestion of LC plasma activates pDC and supports the immune system. This novel approach to strengthening the immune system can improve the experience of continuous high-intensity exercise. “
Related: NBA basketball players have low O3I scores
Kyowa Hakko launches “Breathe” campaign
The opportunity for active nutrition
EYEMUSE made its debut at the ISSN. It’s a heat-treated paraprobiotic, Lactaseibacillus paracasei KW3110, that has been shown to support healthy eye function by stimulating the immune cells that produce regulatory cytokines like IL-10 that can help reduce eye fatigue from digital stress.
Interested in active nutrition? The naturally informed event, Active Nutrition: Mastering the Market, took place June 29-30. If you missed it, don’t worry – it will be available upon request in the first week of July. Register at www.NaturallyInformed.net.
